Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio
Go back to Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio| StemCells, Inc. (NASDAQ: TEM) | Delayed: 47.82 -1.77 (3.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $49.59 | 52 Week High | $0.45 | |||
| Open | $49.75 | 52 Week Low | $0.37 | |||
| Day High | $49.98 | P/E | N/A | |||
| Day Low | $47.12 | EPS | $-0.31 | |||
| Volume | 6,119,195 | |||||
